[Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon].
Salgado Ordóñez
F
F
Servicio de Medicina, Hospital de la Serranía, Ronda.
Manteca González
R
R
Palacios Rodríguez
S
S
Godoy Guerrero
M
M
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b